Stories

Bob Herman Apr 21, 2017
SaveSave story

Drug companies flood Congress with lobbyists

Andrew Harnik / AP

The pharmaceutical industry heavily increased how much it spent on lobbyists in the first quarter of 2017, just as President Trump entered office and skewered drug companies for their high prices. There's bipartisan support for tackling rising drug costs, but drug makers clearly want to maintain the status quo and have tried to turn attention to wholesalers and middlemen in the supply chain.

The details: Axios reviewed lobbying disclosures for 61 of the largest health care companies and trade groups. Those organizations spent more than $90.6 million on lobbying in the first three months of this year, a 20% jump from the $75.7 million in the first quarter of 2016. Twenty-five drug companies and groups — led by the Pharmaceutical Research and Manufacturers of America, Novartis, Pfizer, Amgen, Teva and Bayer — all significantly bumped up their lobbying expenses.